Abstract:

Objective　To investigate the effect of recombinant human erythropoietin combined with L-carnitine for patients with chronic renal failure taking hemodialysis. Methods　A total of 94 patients with chronic renal failure who received hemodialysis in Anyang Third People's Hospital from December 2019 to December 2021 were selected as the research objects. They were divided into an experimental group and a control group by the random number table method, with 47 cases in each group. There were 27 males and 20 females in the experimental group; they were 37-76 (49.12±9.26) years old; they had been taking hemodialysis for 5 months to 5 years. There were 26 males and 21 females in the control group; they were 39-79 (49.12±9.26) years old; they had been taking hemodialysis for 3 months to 6 years. The experimental group took recombinant human erythropoietin and L-carnitine, and the control group recombinant human erythropoietin. Both groups were followed up for 3 months. The clinical efficacies, levels of albumin and hemoglobin, and incidences of adverse reactions were compared between the 2 groups. t and χ² tests were applied. Results　The total effective rate of the experimental group was higher than that of the control group [95.74% (45/47) vs. 80.85% (38/47)], with a statistical difference (χ²=5.045, P<0.05). After the treatment, the levels of albumin and hemoglobin in the two groups were significantly higher than those before the treatment, and the levels in the experimental group were higher than those in the control group [(114.15±16.04) g/L vs. (103.62±10.99) g/L and (39.93±5.79) g/L vs. (31.56±4.54) g/L], with statistical differences (t=3.713 and 7.799; both P<0.05). The incidence of adverse reactions in the experimental group was lower than that in the control group [6.38% (3/47) vs. 21.28% (10/47)], with a statistical difference (χ²=4.374, P<0.05). Conclusion　Recombinant human erythropoietin combined with levocanidine for patients with chronic renal failure taking hemodialysis can improve the effect and their levels of albumin and hemoglobin, and reduce the incidence of adverse reactions, so it is worth being clinically generalized in similar patients taking hemodialysis.

Key words:

Chronic renal failure, Hemodialysis, L-carnitine, Recombinant human erythropoietin, Albumin

摘要：

目的　探讨重组人促红素联合左卡尼汀治疗慢性肾衰竭血液透析患者的疗效。方法　前瞻性选取2019年12月至2021年12月安阳市第三人民医院收治的94例慢性肾衰竭血液透析患者为研究对象，随机数字表法分为试验组和对照组，各47例。试验组男27例、女20例，年龄37～76（49.12±9.26）岁，透析病程5个月～5年，采用重组人促红素联合左卡尼汀治疗；对照组男26例、女21例，年龄39～79（51.32±10.14）岁，透析病程3个月～6年，采用重组人促红素治疗。两组均进行2个疗程，随访3个月，对比两组患者临床疗效，以及白蛋白、血红蛋白水平，并统计两组药物不良反应发生情况。统计学方法采用t检验、χ²检验。结果　与对照组相比，试验组总有效率较高［95.74%（45/47）比80.85%（38/47）］，差异有统计学意义（χ²=5.045，P<0.05）。治疗后，两组患者血红蛋白、白蛋白水平均较治疗前升高，且试验组均高于对照组［（114.15±16.04）g/L比（103.62±10.99）g/L、（39.93±5.79）g/L比（31.56±4.54）g/L］，差异均有统计学意义（t=3.713、7.799，均P<0.05）。试验组不良反应发生率低于对照组［6.38%（3/47）比21.28%（10/47）］，差异有统计学意义（χ²=4.374，P<0.05）。结论　通过对慢性肾衰竭血液透析患者采取重组人促红素联合左卡尼丁治疗可以进一步提高患者治疗效果，有利于更好地改善患者自身的白蛋白及血红蛋白水平，降低患者的不良反应发生率，值得在临床同类血液透析患者中进行推广和应用。

关键词:

慢性肾衰竭, 血液透析, 左卡尼汀, 重组人促红素, 白蛋白